Report cover image

Viral Vector & Plasmid DNA Manufacturing Market  Share, Global Industry Growth, Analysis, Size and Forecast 2024-2032

Publisher Acumen Research and Consulting
Published Jun 01, 2024
Length 250 Pages
SKU # ACRC19848540

Description

The Viral Vector & Plasmid DNA Manufacturing Market Size accounted for USD 5.4 Billion in 2023 and is estimated to achieve a market size of USD 24.6 Billion by 2032 growing at a CAGR of 18.5% from 2024 to 2032.

The Viral Vector and Plasmid DNA Manufacturing Market has gained significant prominence in recent years, primarily due to the increasing demand for gene therapies, vaccine development, and other advanced biopharmaceutical products. The market is an essential component of the biotechnology and pharmaceutical industries, as viral vectors and plasmid DNA are crucial for the development of various gene-based treatments, including gene editing, cancer immunotherapies, and vaccines. The growth of this market is closely tied to advancements in molecular biology, genetics, and immunology, which are transforming the landscape of healthcare by enabling the development of innovative therapies for previously untreatable or difficult-to-treat diseases. This abstract explores the drivers, challenges, trends, and future outlook of the viral vector and plasmid DNA manufacturing market, providing a comprehensive overview of its pivotal role in the biopharmaceutical sector.

Viral vectors are tools used in gene therapy to deliver genetic material into cells, with applications ranging from gene replacement and gene editing to cancer immunotherapy. Plasmid DNA, on the other hand, consists of circular DNA molecules that are used in gene transfer, vaccine production, and other therapeutic applications. Both viral vectors and plasmid DNA are essential in the development of a range of biopharmaceutical products, including cell and gene therapies, vaccines, and advanced therapeutic vaccines. The manufacturing of viral vectors and plasmid DNA requires highly specialized technologies and facilities, as these processes are complex and demand strict adherence to quality standards and regulatory guidelines.

Viral Vector & Plasmid DNA Manufacturing Market Segmentation

The worldwide market for viral vector & plasmid DNA manufacturing is split based on vector type, workflow, application, disease, end use, and geography.

Viral Vector & Plasmid DNA Manufacturing Vector Types

Viral Vectors
Adenovirus
Retrovirus
Adeno-Associated Virus (AAV)
Lentivirus
Others
Plasmid DNA

Viral Vector & Plasmid DNA Manufacturing Workflows

Upstream Manufacturing
Vector Amplification & Expansion
Vector Recovery/Harvesting
Downstream Manufacturing
Purification
Fill Finish

Viral Vector & Plasmid DNA Manufacturing Applications

Antisense & RNAi Therapy
Gene Therapy
Cell Therapy
Vaccinology
Research Applications

Viral Vector & Plasmid DNA Manufacturing Diseases

Infectious Disease
Genetic Disorders
Cancer
Others

Viral Vector & Plasmid DNA Manufacturing End Uses

Pharmaceutical and Biopharmaceutical Companies
Research Institutes

Viral Vector & Plasmid DNA Manufacturing Market Regional Outlook

North America (United States and Canada)
Europe (Germany, UK, France, Spain, and the Rest of Europe.)
Asia-Pacific (China, Japan, Korea, India, Australia, and Rest of Asia-Pacific)
Latin America (Brazil, Mexico, and the Rest of Latin America.)
Middle East and Africa (South Africa, GCC Countries, and, the Rest of the Middle East & Africa (ME&A))

Viral Vector & Plasmid DNA Manufacturing Market Players

Some of the top viral vector & plasmid DNA manufacturing companies offered in our report includes Waisman Biomanufacturing, Merck KGaA, RegenxBio, Inc., Thermo Fisher Scientific, Catalent Inc., Lonza Group AG, RegenxBio, Inc., Cobra Biologics, Audentes Therapeutics, Takara Bio Inc., BioNTech IMFS GmbH, FUJIFILM Diosynth Biotechnologies, Virovek Incorporation, SIRION Biotech GmbH, Genezen laboratories, and Miltenyi Biotec GmbH.

Table of Contents

250 Pages
CHAPTER 1. Industry Overview of Viral Vector & Plasmid DNA Manufacturing Market
1.1. Definition and Scope
1.2. Summary
CHAPTER 2. Research Approach
2.1. Methodology
2.2. Data Source
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.2. Restraints and Challenges
3.3. Growth Opportunities
3.4. Porter’s Five Forces Analysis
3.5. Market Concentration Ratio and Market Maturity Analysis of Viral Vector & Plasmid DNA Manufacturing Market
3.6. Technological Roadmap for Viral Vector & Plasmid DNA Manufacturing Market
3.7. Value Chain Analysis
3.8. Cost Structure Analysis
3.9. Regulatory Compliance
3.10. Competitive Landscape, 2023
CHAPTER 4. Manufacturing Plant Analysis
4.1. Manufacturing Plant Location and Establish Date of Major Manufacturers in 2023
4.2. R&D Status of Major Manufacturers in 2023
CHAPTER 5. Viral Vector & Plasmid DNA Manufacturing Market By Vector Type
5.1. Introduction
5.2. Viral Vector & Plasmid DNA Manufacturing Revenue By Vector Type
5.2.1. Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast, By Vector Type, 2020-2032
5.2.2. Viral Vectors
5.2.2.1. Viral Vectors Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.2.2. Adenovirus
5.2.2.2.1. Adenovirus Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.2.3. Retrovirus
5.2.2.3.1. Retrovirus Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.2.4. Adeno-Associated Virus (AAV)
5.2.2.4.1. Adeno-Associated Virus (AAV) Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.2.5. Lentivirus
5.2.2.5.1. Lentivirus Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.2.6. Others
5.2.2.6.1. Others Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
5.2.3. Plasmid DNA
5.2.3.1. Plasmid DNA Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 6. Viral Vector & Plasmid DNA Manufacturing Market By Workflow
6.1. Introduction
6.2. Viral Vector & Plasmid DNA Manufacturing Revenue By Workflow
6.2.1. Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast, By Workflow, 2020-2032
6.2.2. Upstream Manufacturing
6.2.2.1. Upstream Manufacturing Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.2.2. Vector Amplification & Expansion
6.2.2.2.1. Vector Amplification & Expansion Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.2.3. Vector Recovery/Harvesting
6.2.2.3.1. Vector Recovery/Harvesting Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.3. Downstream Manufacturing
6.2.3.1. Downstream Manufacturing Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.3.2. Purification
6.2.3.2.1. Purification Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
6.2.3.3. Fill Finish
6.2.3.3.1. Fill Finish Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 7. Viral Vector & Plasmid DNA Manufacturing Market By Application
7.1. Introduction
7.2. Viral Vector & Plasmid DNA Manufacturing Revenue By Application
7.2.1. Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast, By Application, 2020-2032
7.2.2. Antisense & RNAi Therapy
7.2.2.1. Antisense & RNAi Therapy Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
7.2.3. Gene Therapy
7.2.3.1. Gene Therapy Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
7.2.4. Cell Therapy
7.2.4.1. Cell Therapy Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
7.2.5. Vaccinology
7.2.5.1. Vaccinology Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
7.2.6. Research Applications
7.2.6.1. Research Applications Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 8. Viral Vector & Plasmid DNA Manufacturing Market By Disease
8.1. Introduction
8.2. Viral Vector & Plasmid DNA Manufacturing Revenue By Disease
8.2.1. Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast, By Disease, 2020-2032
8.2.2. Infectious Disease
8.2.2.1. Infectious Disease Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
8.2.3. Genetic Disorders
8.2.3.1. Genetic Disorders Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
8.2.4. Cancer
8.2.4.1. Cancer Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
8.2.5. Others
8.2.5.1. Others Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 9. Viral Vector & Plasmid DNA Manufacturing Market By End Use
9.1. Introduction
9.2. Viral Vector & Plasmid DNA Manufacturing Revenue By End Use
9.2.1. Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast, By End Use, 2020-2032
9.2.2. Pharmaceutical and Biopharmaceutical Companies
9.2.2.1. Pharmaceutical and Biopharmaceutical Companies Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
9.2.3. Research Institutes
9.2.3.1. Research Institutes Market Revenue (USD Billion) and Growth Rate (%), 2020-2032
CHAPTER 10. North America Viral Vector & Plasmid DNA Manufacturing Market By Country
10.1. North America Viral Vector & Plasmid DNA Manufacturing Market Overview
10.2. U.S.
10.2.1. U.S. Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Vector Type, 2020-2032
10.2.2. U.S. Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Workflow, 2020-2032
10.2.3. U.S. Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Application, 2020-2032
10.2.4. U.S. Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Disease, 2020-2032
10.2.5. U.S. Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By End Use, 2020-2032
10.3. Canada
10.3.1. Canada Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Vector Type, 2020-2032
10.3.2. Canada Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Workflow, 2020-2032
10.3.3. Canada Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Application, 2020-2032
10.3.4. Canada Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Disease, 2020-2032
10.3.5. Canada Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By End Use, 2020-2032
10.4. North America PEST Analysis
CHAPTER 11. Europe Viral Vector & Plasmid DNA Manufacturing Market By Country
11.1. Europe Viral Vector & Plasmid DNA Manufacturing Market Overview
11.2. U.K.
11.2.1. U.K. Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Vector Type, 2020-2032
11.2.2. U.K. Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Workflow, 2020-2032
11.2.3. U.K. Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Application, 2020-2032
11.2.4. U.K. Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Disease, 2020-2032
11.2.5. U.K. Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By End Use, 2020-2032
11.3. Germany
11.3.1. Germany Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Vector Type, 2020-2032
11.3.2. Germany Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Workflow, 2020-2032
11.3.3. Germany Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Application, 2020-2032
11.3.4. Germany Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Disease, 2020-2032
11.3.5. Germany Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By End Use, 2020-2032
11.4. France
11.4.1. France Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Vector Type, 2020-2032
11.4.2. France Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Workflow, 2020-2032
11.4.3. France Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Application, 2020-2032
11.4.4. France Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Disease, 2020-2032
11.4.5. France Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By End Use, 2020-2032
11.5. Spain
11.5.1. Spain Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Vector Type, 2020-2032
11.5.2. Spain Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Workflow, 2020-2032
11.5.3. Spain Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Application, 2020-2032
11.5.4. Spain Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Disease, 2020-2032
11.5.5. Spain Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By End Use, 2020-2032
11.6. Rest of Europe
11.6.1. Rest of Europe Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Vector Type, 2020-2032
11.6.2. Rest of Europe Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Workflow, 2020-2032
11.6.3. Rest of Europe Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Application, 2020-2032
11.6.4. Rest of Europe Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Disease, 2020-2032
11.6.5. Rest of Europe Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By End Use, 2020-2032
11.7. Europe PEST Analysis
CHAPTER 12. Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market By Country
12.1. Asia Pacific Viral Vector & Plasmid DNA Manufacturing Market Overview
12.2. China
12.2.1. China Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Vector Type, 2020-2032
12.2.2. China Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Workflow, 2020-2032
12.2.3. China Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Application, 2020-2032
12.2.4. China Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Disease, 2020-2032
12.2.5. China Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By End Use, 2020-2032
12.3. Japan
12.3.1. Japan Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Vector Type, 2020-2032
12.3.2. Japan Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Workflow, 2020-2032
12.3.3. Japan Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Application, 2020-2032
12.3.4. Japan Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Disease, 2020-2032
12.3.5. Japan Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By End Use, 2020-2032
12.4. India
12.4.1. India Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Vector Type, 2020-2032
12.4.2. India Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Workflow, 2020-2032
12.4.3. India Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Application, 2020-2032
12.4.4. India Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Disease, 2020-2032
12.4.5. India Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By End Use, 2020-2032
12.5. Australia
12.5.1. Australia Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Vector Type, 2020-2032
12.5.2. Australia Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Workflow, 2020-2032
12.5.3. Australia Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Application, 2020-2032
12.5.4. Australia Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Disease, 2020-2032
12.5.5. Australia Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By End Use, 2020-2032
12.6. South Korea
12.6.1. South Korea Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Vector Type, 2020-2032
12.6.2. South Korea Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Workflow, 2020-2032
12.6.3. South Korea Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Application, 2020-2032
12.6.4. South Korea Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Disease, 2020-2032
12.6.5. South Korea Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By End Use, 2020-2032
12.7. Rest of Asia-Pacific
12.7.1. Rest of Asia-Pacific Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Vector Type, 2020-2032
12.7.2. Rest of Asia-Pacific Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Workflow, 2020-2032
12.7.3. Rest of Asia-Pacific Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Application, 2020-2032
12.7.4. Rest of Asia-Pacific Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Disease, 2020-2032
12.7.5. Rest of Asia-Pacific Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By End Use, 2020-2032
12.8. Asia Pacific PEST Analysis
CHAPTER 13. Latin America Viral Vector & Plasmid DNA Manufacturing Market By Country
13.1. Latin America Viral Vector & Plasmid DNA Manufacturing Market Overview
13.2. Brazil
13.2.1. Brazil Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Vector Type, 2020-2032
13.2.2. Brazil Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Workflow, 2020-2032
13.2.3. Brazil Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Application, 2020-2032
13.2.4. Brazil Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Disease, 2020-2032
13.2.5. Brazil Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By End Use, 2020-2032
13.3. Mexico
13.3.1. Mexico Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Vector Type, 2020-2032
13.3.2. Mexico Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Workflow, 2020-2032
13.3.3. Mexico Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Application, 2020-2032
13.3.4. Mexico Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Disease, 2020-2032
13.3.5. Mexico Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By End Use, 2020-2032
13.4. Rest of Latin America
13.4.1. Rest of Latin America Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Vector Type, 2020-2032
13.4.2. Rest of Latin America Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Workflow, 2020-2032
13.4.3. Rest of Latin America Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Application, 2020-2032
13.4.4. Rest of Latin America Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Disease, 2020-2032
13.4.5. Rest of Latin America Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By End Use, 2020-2032
13.5. Latin America PEST Analysis
CHAPTER 14. Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market By Country
14.1. Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Market Overview
14.2. GCC
14.2.1. GCC Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Vector Type, 2020-2032
14.2.2. GCC Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Workflow, 2020-2032
14.2.3. GCC Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Application, 2020-2032
14.2.4. GCC Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Disease, 2020-2032
14.2.5. GCC Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By End Use, 2020-2032
14.3. South Africa
14.3.1. South Africa Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Vector Type, 2020-2032
14.3.2. South Africa Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Workflow, 2020-2032
14.3.3. South Africa Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Application, 2020-2032
14.3.4. South Africa Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Disease, 2020-2032
14.3.5. South Africa Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By End Use, 2020-2032
14.4. Rest of Middle East & Africa
14.4.1. Rest of Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Vector Type, 2020-2032
14.4.2. Rest of Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Workflow, 2020-2032
14.4.3. Rest of Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Application, 2020-2032
14.4.4. Rest of Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By Disease, 2020-2032
14.4.5. Rest of Middle East & Africa Viral Vector & Plasmid DNA Manufacturing Revenue (USD Billion) and Forecast By End Use, 2020-2032
14.5. Middle East & Africa PEST Analysis
CHAPTER 15. Player Analysis Of Viral Vector & Plasmid DNA Manufacturing Market
15.1. Viral Vector & Plasmid DNA Manufacturing Market Company Share Analysis
15.2. Competition Matrix
15.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
15.2.2. New Product Launches and Product Enhancements
15.2.3. Mergers And Acquisition In Global Viral Vector & Plasmid DNA Manufacturing Market
15.2.4. Partnership, Joint Ventures and Strategic Alliances/ Sales Agreements
CHAPTER 16. Company Profile
16.1. Waisman Biomanufacturing
16.1.1. Company Snapshot
16.1.2. Business Overview
16.1.3. Financial Overview
16.1.3.1. Revenue (USD Billion), 2023
16.1.3.2. Waisman Biomanufacturing 2023 Viral Vector & Plasmid DNA Manufacturing Business Regional Distribution
16.1.4. Product /Service and Specification
16.1.5. Recent Developments & Business Strategy
16.2. Merck KGaA
16.3. RegenxBio, Inc.
16.4. Thermo Fisher Scientific
16.5. Catalent Inc.
16.6. Lonza Group AG
16.7. RegenxBio, Inc.
16.8. Cobra Biologics
16.9. Audentes Therapeutics
16.10. Takara Bio Inc.
16.11. BioNTech IMFS GmbH
16.12. FUJIFILM Diosynth Biotechnologies
16.13. Virovek Incorporation
16.14. SIRION Biotech GmbH
16.15. Genezen laboratories
16.16. Miltenyi Biotec GmbH

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us